Table 4.
CD38+IgD- (Bm5) |
CD38+IgD+ (Mature Bm2) |
CD38++IgD- (Immature/T1) |
CD38++IgD+ (Immature/T1) |
CD38+++IgD- (Plasma blasts) |
||||||
N = 10 | n = 14 | n = 10 | n = 14 | n = 10 | n = 14 | n = 10 | n = 14 | n = 10 | n = 14 | |
Baseline | ||||||||||
Day 0 | 34 ± 32 | 55 ± 51 | 140 ± 135 | 203 ± 140 | 96 ± 98 | 180 ± 289 | 19 ± 15 | 35 ± 49 | 27 ± 16 | 38 ± 31 |
Short-term | ||||||||||
1 month | 2 ± 2 P = 0.01 |
0.9 ± 1 P = 0.01 |
48 ± 71 P = ns |
9 ± 25 P = ns |
21 ± 19 P = ns |
|||||
3 months | 12 ± 32 P = 0.04 |
1 ± 2 P = 0.0001 |
86 ± 97 P = ns |
3 ± 5 P = 0.03 |
23 ± 29 P = ns |
|||||
Post-RTX survival % | 6 | 22 | 1 | 0.5 | 50 | 48 | 47 | 9 | 78 | 61 |
* Values are given as mean ± standard deviation.
** Statistics are calculated with paired T-test, P-values are given in comparison to day 0.
RTX = rituximab.